Bone Biologics FY2026 EPS Forecast Lowered by Zacks Research

Bone Biologics Corp. (NASDAQ:BBLG) – Stock analysts at Zacks Research lowered their FY2026 earnings per share (EPS) estimates for Bone Biologics in a report released on Tuesday, March 3rd. Zacks Research analyst B. Sorensen now expects that the company will earn ($1.93) per share for the year, down from their previous estimate of ($1.36). The consensus estimate for Bone Biologics’ current full-year earnings is ($5.00) per share.

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Bone Biologics in a report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Bone Biologics currently has a consensus rating of “Sell”.

Bone Biologics Trading Down 0.6%

Bone Biologics stock opened at $1.25 on Thursday. The firm has a market capitalization of $2.25 million, a P/E ratio of -0.33 and a beta of 0.78. The business has a 50-day moving average of $1.47 and a 200-day moving average of $1.87. Bone Biologics has a 1 year low of $1.11 and a 1 year high of $6.75.

Institutional Trading of Bone Biologics

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC grew its position in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the quarter. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 at the end of the most recent reporting period. 34.30% of the stock is currently owned by institutional investors and hedge funds.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.